NEW YORK (GenomeWeb) — Wells Fargo has downgraded Cepheid to Market Perform from Outperform, calling into question the company's "credibility and visibility" after it revised its 2017 profit outlook.

Cepheid reaffirmed its 2015 fourth quarter outlook at the Piper Jaffray Healthcare Conference on Tuesday, and also provided initial revenue guidance of $618 million to $635 million for Fiscal Year 2016. The company also updated its FY 2017 outlook to a gross margin of 56 percent to 58 percent, compared to its previous guidance of 60 percent.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.